Comparative results of cryoablation and laparoscopic radical prostatectomy in the treatment of localized prostate cancer

Chinenov, Denis; Rapoport, L.; Shpot, E V; Enikeev, Dmitry; Chernov, Yaroslav; Taratkin, Mark; Korolev, Dmitry

doi:10.1177/0391560317749425

Cited by 5 publications

(10 citation statements)

References 2 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past few decades, prostate cancer has been at the forefront of global male malignancy mortality 25 . As for the diagnosis of prostate cancer, exponential apparent diffusion coefficient and computed diffusion-weighted imaging are often used 26 .…”

Section: Discussionmentioning

confidence: 99%

RETRACTED: Exosomes Derived from miR-143-Overexpressing MSCs Inhibit Cell Migration and Invasion in Human Prostate Cancer by Downregulating TFF3

Che

Shi

et al. 2019

Molecular Therapy - Nucleic Acids

128

View full text Add to dashboard Cite

Exosomes are membrane-enclosed nanovesicles that shuttle active cargoes, such as mRNAs and microRNAs (miRNAs), between different cells. Mesenchymal stem cells (MSCs) are able to migrate to the tumor sites and exert complex functions over tumor progress. We investigated the effect of human bone marrow-derived MSC (BMSC)-derived exosomal miR-143 on prostate cancer. During the co-culture experiments, we disrupted exosome secretion by the inhibitor GW4869 and overexpressed exosomal miR-143 using miR-143 plasmid. miR-143 was involved in the progression of prostate cancer via trefoil factor 3 (TFF3). Moreover, miR-143 was downregulated while TFF3 was upregulated in prostate cancer cells and tissues, and miR-143 was found to specifically inhibit TFF3 expression. Human MSC-derived exosomes enriched miR-143 and transferred miR-143 to prostate cancer cells. Furthermore, elevated miR-143 or exosome-miR-143 or silencing TFF3 inhibited the expression of TFF3, proliferating cell nuclear antigen (PCNA), matrix metalloproteinase (MMP)-2, and MMP-9 and PC3 cell proliferation, migration, invasion, and tumor growth, whereas it promoted apoptosis. In conclusion, hMSC-derived exosomal miR-143 directly and negatively targets TFF3 to suppress prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

RETRACTED: Exosomes Derived from miR-143-Overexpressing MSCs Inhibit Cell Migration and Invasion in Human Prostate Cancer by Downregulating TFF3

Che

Shi

et al. 2019

Molecular Therapy - Nucleic Acids

128

View full text Add to dashboard Cite

show abstract

“…[1,2] Although the surgical approaches and adjuvant chemotherapy have been improved over the past decades, treatment of prostate cancer is still a challenging issue in the clinical setting. [1,2] Although the surgical approaches and adjuvant chemotherapy have been improved over the past decades, treatment of prostate cancer is still a challenging issue in the clinical setting.…”

Section: Introductionmentioning

confidence: 99%

Retracted: Knockdown of SRPX2 inhibits the proliferation, migration, and invasion of prostate cancer cells through the PI3K/Akt/mTOR signaling pathway

2018

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Sushi repeat‐containing protein X‐linked 2 (SRPX2), a novel chondroitin sulfate proteoglycan, is reported to play a critical role in tumorigenesis. However, the expression and functional role of SRPX2 in prostate cancer have not been defined. Thus, the aim of this study was to investigate the expression and functional role of SRPX2 in human prostate cancer. Our results showed that the expression of SRPX2 was obviously increased in human prostate cancer tissues and cell lines. In addition, knockdown of SRPX2 inhibited the proliferation, migration, and invasion of prostate cancer cells, as well as prevented the epithelial‐mesenchymal transition process in prostate cancer cells. Mechanically, knockdown of SRPX2 efficiently inhibited the activation of PI3K/Akt/mTOR pathway in prostate cancer cells. Taken together, these data demonstrated that knockdown of SRPX2 inhibits the proliferation and metastasis in human prostate cancer cells, partly through the PI3K/Akt/mTOR signaling pathway. Thus, SRPX2 may be a novel therapeutic target for the treatment of prostate cancer.

show abstract

“…Among the 26 studies [23][24][25][26][27][28][29][30][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54] included (Table 3…”

Section: Resultsmentioning

confidence: 99%

“…Two studies [25,44] assessed biochemical-free survival, which ranged from 53% to 69%. Six studies [26,27,42,44,48,50] reported PSA nadir levels ranging from 0.1 to 2.63 ng/mL. Only one study [21] reported a PSA decrease of 2 ng/mL.…”

Section: Primary Outcomes In Primary Treatment Studiesmentioning

confidence: 99%

“…One study [25] used the clinical definition of erectile dysfunction (number of patients) to assess post-procedural sexual function. Seven studies described continence, five studies [26,27,40,42,43] utilised the IPSS and two studies [25,50] assessed the necessity of requiring continence pads to evaluate urological function. Despite using similar questionnaires, the heterogeneity among the studies was remarkable.…”

Section: Table 6: Immediate and Long-term Complication Rates After Pr...mentioning

confidence: 99%

See 1 more Smart Citation

Systematic Review of Focal and Salvage Cryotherapy for Prostate Cancer

Chin¹,

Lynn²

2022

Cureus

View full text Add to dashboard Cite

Cryotherapy is one of the recognised ablative modalities for both primary and salvage therapy for prostate cancer. It presents an alternative, less invasive treatment for an organ-confined disease, improved preservation of surrounding tissue and a more suitable option for patients who are unfit for radical prostatectomy. Nevertheless, the currently available literature is relatively too scarce to provide definite conclusions regarding the treatment outcomes in cryotherapy. The present study aimed to review current oncological and survival outcomes in cryotherapy for primary and recurrent prostate cancer. Furthermore, this study aimed to establish the complications and functional outcomes of cryotherapy for prostate cancer. A literature search was performed on the PubMed, Cochrane and Google Scholar databases. Current guidelines and recommendations from the European Association of Urology were also reviewed. The search keywords used included 'Cryotherapy, Prostate Cancer', 'Cryoablation, Prostate Cancer' and 'Cryosurgery, Focal Prostate Cancer'. Truncations and Boolean operators were used with the keywords. All relevant studies from after 2015, including abstracts and non-English research assessing oncological and functional outcomes and complications, were included. Twenty-six studies consisting of 11,228 patients were reviewed. Fifteen studies assessed the outcomes of primary cryotherapy, whereas 11 studies reported the outcomes in salvage therapy. The patient's age ranged 55-85 years, and the pre-procedural prostate-specific antigen (PSA) ranged 0.01-49.33 ng/mL. A total of 2031 patients were classified to be at low risk, 2,995 were at moderate risk and 253 were at high risk on the D'Amico prostate cancer risk classification system. Followups ranged from 9.0 to 297.6 months. The disease-specific survival rate was 65.5%-100.0%, overall survival was 61.3%-99.1%, the PSA nadir was 0.01-2.63 ng/mL and the overall biochemical recurrence rate was 15.4%-62.0%. The complications included erectile dysfunction (3.7%-88.0%), urinary retention (2.13%-25.30%) and bladder neck stricture/stenosis (3.0%-16.7%). The functional assessment showed a mixture of improved, unchanged or worsened post-procedural outcomes in primary therapy. This systematic review did not find significant differences in the cancer-specific, overall and biochemical-free survival rate between the primary and salvage cryotherapy cohorts. The most common complications encountered in both cohorts were erectile dysfunction, urinary incontinence, lower urinary tract/bladder neck stricture and infection. More prospective and double-arm studies are critically needed to provide guidance on the careful selection of patient cohorts for cryotherapy, whether for curative or salvage intent.

show abstract

Comparative results of cryoablation and laparoscopic radical prostatectomy in the treatment of localized prostate cancer

Cited by 5 publications

References 2 publications

RETRACTED: Exosomes Derived from miR-143-Overexpressing MSCs Inhibit Cell Migration and Invasion in Human Prostate Cancer by Downregulating TFF3

RETRACTED: Exosomes Derived from miR-143-Overexpressing MSCs Inhibit Cell Migration and Invasion in Human Prostate Cancer by Downregulating TFF3

Retracted: Knockdown of SRPX2 inhibits the proliferation, migration, and invasion of prostate cancer cells through the PI3K/Akt/mTOR signaling pathway

Systematic Review of Focal and Salvage Cryotherapy for Prostate Cancer

Contact Info

Product

Resources

About